A Randomized Phase 3 Study of MRTX849 Versus Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer With KRAS G12C Mutation
A Randomized Phase 3 Study of MRTX849 Versus Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer With KRAS G12C Mutation
This Phase 3 study will evaluate the efficacy of the investigational agent MRTX849 (adagrasib) versus docetaxel in patients who have been previously treated for metastatic NSCLC with a KRAS G12C mutation.
Inclusion Criteria:
Crossover Inclusion Criteria:
Exclusion Criteria:
Crossover Exclusion Criteria:
Praha 8 - Liben, 180 81, Czechia
Grohansdorf, 22927, Germany
Kislino Village, 305524, Russia
Hwasun-gun, 58128, South Korea